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Rexin-G, a pathotropic nanoparticle bearing a cytocidal 
cyclin G1 construct was tested in a phase I/II study for 
chemotherapy-resistant sarcomas and a phase II study for 
chemotherapy-resistant osteosarcoma. Twenty   sarcoma 
patients  and  22  osteosarcoma  patients  received  esca-
lating doses of Rexin-G intravenously from 8 × 1011 to 
24  ×  1011 colony forming units (cfu)/cycle. Treatment 
was continued if there was ≤ grade 1 toxicity. No dose-
limiting toxicity (DLT) was observed, and no vector DNA 
integration,  replication-competent  retrovirus  (RCR)  or 
vector-neutralizing antibodies were noted. In the phase 
I/II  study,  3/6  patients  had  stable  disease  (SD)  at  the 
lowest dose; median progression-free survival (PFS) was 
1.2 months, and overall survival (OS), 3.3 months. At 
higher doses, 10/14 patients had SD; median PFS was 
3.7 months and median OS, 7.8 months. In this phase 
I/  II study, a dose–response relationship with Rexin-G dos-
age was observed for progression-free and OS times (P = 
0.02 and 0.005, respectively). In the phase II study, 10/17 
evaluable patients had SD, median PFS was ≥3 months 
and median OS, 6.9 months. These studies suggest that 
Rexin-G  is  safe,  may  help  control  tumor  growth,  and 
may possibly improve survival in chemotherapy-  resistant 
  sarcoma and osteosarcoma.
Received 17 February 2009; accepted 4 May 2009; published online  
16 June 2009. doi:10.1038/mt.2009.126
IntroductIon
Osteosarcoma is a rare malignant tumor of bone usually affecting 
adolescents  and  young  adults.1  Current  combination  chemother-
apy,  radiation  therapy,  and  surgery,  have  significantly  improved 
the survival of affected persons. Effective drugs include doxorubi-
cin,   cisplatin, methotrexate, and ifosfamide.2 However, no standard 
second line therapy exists for those who relapse or fail to achieve a 
second remission with the best reported overall survival (OS) of 0.6 
years.3 Additionally, the long-term sequelae and secondary malig-
nancies associated with toxic chemotherapy in children and adoles-
cents   augment the need for more effective and less toxic therapies.3
Soft  tissue  sarcoma  is  also  a  rare  cancer  of  mesenchymal 
  tissues.4 Current treatment for soft tissue sarcoma includes surgi-
cal resection, radiotherapy, and chemotherapy.5 Despite improve-
ments  in  the  control  of  local  disease,  a  significant  number  of 
patients  ultimately  die  of  metastatic  disease  following  radical 
  surgery due to a lack of effective adjuvant treatments.6–10 Only 
three drugs—doxorubicin, dacarbazine, and ifosfamide—are con-
sistently associated with response rates of ≥20%, and after failure 
of these drugs, patients with advanced soft tissue sarcoma have 
few therapeutic options.11
Among the leading alternatives to traditional chemotherapeu-
tics, both cancer immunotherapy and cancer gene therapy strate-
gies are currently under active clinical investigation.12–14 Rexin-G, 
the first and, so far, only targeted gene therapy vector bearing a 
cytocidal dominant negative cyclin G1 construct,15 is currently 
being tested simultaneously in three phase I/II clinical trials for 
chemotherapy-resistant  metastatic  sarcoma,  pancreatic  cancer, 
and breast cancer, and in one phase II study for chemotherapy-
resistant metastatic osteosarcoma in the United States.
In this article, we report on the results of two independent 
studies (i) evaluating the overall safety and potential efficacy of 
Rexin-G in chemotherapy-resistant sarcoma in a phase I/II study, 
and (ii) confirming the efficacy and overall safety of Rexin-G in 
chemotherapy-resistant osteosarcoma in a phase II study.
results
Patient demographics
Table 1 shows the patient demographics for the phase I/II   sarcoma 
study and the phase II osteosarcoma study. There were nine   different 
types of sarcomas enrolled in the phase I/II study, including leio-
myosarcoma (n = 5), osteosarcoma (n = 3), synovial cell sarcoma 
(n = 3), liposarcoma (n = 3), mixed malignant Mullerian tumor of 
ovary (n = 2), Ewing’s sarcoma (n = 1), chondrosarcoma (n = 1), 
malignant fibrous histiocytoma (n = 1), and malignant spindle cell 
sarcoma (n = 1). Ninety-five percent of patients in the phase I/II 
sarcoma study had metastatic disease and a median of four pre-
vious chemotherapy regimens, whereas 100% of patients in the 
phase II osteosarcoma study had metastatic disease and a median 
of  four  previous  chemotherapy  regimens.  Eastern  Cooperative 
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Oncology Group score was 0–1. Table 2 shows the performance 
scoring system employed.
Analysis of safety
Treatment-related adverse events are listed in Table 3. There was 
no dose-limiting toxicity (DLT) or organ-related toxicity. In the 
phase I/II study, at dose level 0, study drug-related adverse events 
included grade 1 chills in one patient, and grade 1–2 fatigue in 
two patients, whereas at dose level I–II, one patient had grade 1 
presyncope. In the phase II study, one patient experienced grade 1 
photophobia, and two patients had grade 1 fatigue which was 
  considered possibly study drug-related.
Correlative  analysis  showed  no  neutralizing    antibodies 
detected in the patients’ sera. However, 3/14 patients who received 
dose  level  II  developed  weakly  positive  antibodies  against  the 
gp70 envelope protein by western blot analysis, 3–4 months after 
treatment  initiation.  Further,  all  DNA  samples  from  patients’ 
peripheral blood lymphocytes (PBLs) were found to be negative 
for   replication-competent retrovirus (RCR), and no vector DNA 
  integration was detected.
Analysis of efficacy
In the phase I/II study, six patients were treated at dose level I 
and 14 patients at dose level I–II (combined). Table 4 (Sarcoma 
study)  shows  the  tumor  responses  using  standard  response 
evaluation  criteria  in  solid  tumors  (RECIST),  International 
positron emission tomography (PET), and CHOI criteria for 
each dose level.
In the phase I/II sarcoma study, at dose level 0, 3/6 patients 
had stable disease (SD) whereas at dose level I–II, 10/14 patients 
had  SD  by  standard  RECIST  criteria.  Interestingly,  using  the 
International  PET  criteria,  at  dose  level  0,  1/6  patients  had  a 
partial response (PR), and 4/6 patients had SD, and at dose level 
I–II, 4/14 patients had PRs, and 9/14 patients had SD. Similarly, 
using CHOI criteria, at dose level 0, 2/6 patients had PRs, and 4/6 
patients had SD, and at dose level I–II, 7/14 patients had PRs and 
7/14 patients had SD. These findings suggest that the International 
table 2  eastern cooperative oncology Group performance 
  scoring system
description score
Fully active, able to carry on all predisease performance without 
restriction.
0
Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
housework, office work.
1
Ambulatory and capable of all self care but unable to carry out 
any work activities. Up and about >50% of waking hours.
2
Capable of only limited self care, confined to bed or chair >50% 
of waking hours.
3
Completely disabled. Cannot carry on any self care. Totally 
confined to bed or chair.
4
table 3  treatment-related adverse events
dose level (n)
Adverse 
event
no. of patients 
with grade 1 
toxicity
no. of patients 
with grade 2 
toxicity
Phase I/II sarcoma study
  0 (6) Chills 1 —
Fatigue 1 1
  I–II (14) Presyncope 1 —
Phase II osteosarcoma study
  I–II (22) Photophobia 1 —
Fatigue 2 —
table 1  Patient demographics
Phase I/II sarcoma study (n = 20)
Age, years
  Median 50.5
  Range (15.0–70.0)
Gender
  Female 8 (40%)
  Male 12 (60%)
Race
  White 15 (75%)
  Black 1 (5%)
  Hispanic 3 (15%)
  Asian 1 (5%)
Disease stage
  Metastatic 19 (95%)
  Nonmetastatic 1 (5%)
Performance score
 1 20 (100%)
No. of previous chemotherapy regimens
  Median 4
  Range 1–10
Phase II osteosarcoma study (n = 22)
Age, years
  Median 33
  Range (7.0–68.0)
Gender
  Female 5 (23 %)
  Male 17 (77%)
Race
  White 9 (41%)
  Black 4 (18%)
  Hispanic 7 (32%)
  Asian 1 (4.5%)
  Others 1 (4.5%)
Disease stage
  Metastatic 22 (100%)
Performance score
 1 22 (100%)
No. of previous chemotherapy regimens
  Median 4
  Range 1–9Molecular Therapy  vol. 17 no. 9 sep. 2009  1653
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PET and CHOI criteria may be more sensitive indicators of tumor 
responses to Rexin-G treatment than the standard RECIST.
The median progression-free survival (PFS) times by RECIST 
was 1.2 months for dose level 0 versus 3.7 months for dose   levels 
I–II (combined), and the corresponding median overall survival 
times were 3.3 months for dose level 0 versus 7.8 months for dose 
levels I–II (Table 4). Using the Cox regression model and Kaplan–
Meier  analysis,16  a  dose–response  relationship  was  observed 
between Rexin-G dosage and both PFS and OS (P = 0.02 for PFS 
by RECIST, 0.004 by PET and 0.003 by CHOI criteria; P = 0.005 
for OS; Figures 1a–c and 2a).
In the phase II study, 17 of 22 patients completed at least one 
treatment  cycle  and  were  considered  evaluable.  Five  patients 
were taken off study without completing one treatment cycle due 
to disease-related complications or a personal decision to dis-
continue participation and return home. The tumor responses 
based on RECIST, International PET criteria and CHOI crite-
ria are shown in Table  4. Using standard RECIST, 10/17 (59%) 
evaluable patients had SD, whereas using International PET cri-
teria, 4/17 patients had PRs, and 8/17 patients had SD, totaling 
70% of patients   having PRs or SD. Using CHOI criteria, 3/17 had 
PRs and 12/17 had SD totaling 88% of patients having PRs or 
SD. Therefore, tumor responses were significantly higher in the 
Rexin-G treated group compared to those expected of historical 
controls (with ≤5% having a positive response if untreated; P < 
0.025).3 Median PFS was ≥3 months, and OS was 6.9 months 
(6 months for all 22 enrolled patients).
Two  patients  are  disease-free  after  surgical  resection  of 
residual tumors, with three cycles of Rexin-G given before and 
3–4 cycles after surgery. These patients enjoy sustained surgical 
remissions 10.7 and 9.7 months after treatment initiation, and >6 
months after surgery. In one patient, histopathologic examination 
of two resected tumor nodules showed a 2.5 cystic nodule and 
rare osteosarcoma cells and a 0.9 cm calcified nodule and resid-
ual osteosarcoma cells with rare mitosis (Figure 3). Of note, the 
2.5 cm tumor had increased in size and was diagnosed as progres-
sive disease (PD) by RECIST but a PR by PET criteria. This finding 
suggests that RECIST criteria may not be a reliable indicator of 
tumor response to Rexin-G treatment in osteosarcoma.
dIscussIon
Rexin-G is a pathotropic nanoparticle incorporating a collagen-
matrix binding motif on its surface and bearing a dominant neg-
ative cyclin G1 construct as its genetic payload. When injected 
intravenously, Rexin-G accumulates in cancerous lesions wherein 
collagen is exposed by tumor invasion, neoangiogenesis or extra-
cellular remodeling, thus increasing the effective local concen-
tration in tumors in the vicinity of target cancer cells. Rexin-G 
table 4  effects of rexin-G on tumor response by recIst, Pet, and cHoI criteria, on PFs and os
dose level (n)
tumor response 
by recIst
tumor response  
by Pet
tumor response 
by cHoI
Median PFs  
by recIst (months)
Median os  
(months)
Phase I/II sarcoma study
  0 (6) 1 × 1011 cfu two times  
  a week
3 SD, 3PD 1 PR, 4 SD, 1 PD 2 PR, 4 SD 1.2 3.3
  I–II (14) 1–2 × 1011 cfu three  
  times a week
10 SD, 4 PD 4 PR, 9 SD, 1 PD 7 PR, 7S D 3.7 7.8
Phase II osteosarcoma study
  (17) 2 × 1011 cfu three times  
  a week
10 SD, 7 PD 4 PR, 8 SD, 5 PD 3 PR, 12 SD, 2 PD ≥3 6.9a
Abbreviations: OS, overall survival; PD, progressive disease; PET, positron emission tomography; PFS, progression-free survival; RECIST, response evaluation criteria in 
solid tumors; SD, stable disease.
a22 Osteosarcoma patients were started on Rexin-G, 5 of whom had <1 treatment cycle or did not return for evaluation; all 5 of these patients died within 2 months 
of starting Rexin-G therapy. Median OS is shown for the 17 evaluable patients; median OS for all 22 enrolled patients was 6.0 months.
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Figure 1  Analyses of progression-free survival (PFs) of patients in the phase I/II sarcoma study using various radiologic imaging criteria. 
Kaplan-Meier analyses show a dose–response relationship between progression-free survival and Rexin-G dosage, as determined (a) by RECIST, (b) by 
International PET criteria, and (c) by CHOI criteria.1654  www.moleculartherapy.org  vol. 17 no. 9 sep. 2009     
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causes  cell  death  by  blocking  the  cell  cycle  in  G1  phase  and 
inducing    apoptosis  of  proliferative  cancer  cells  and  associated 
  neovasculature in preclinical studies.17,18
In the phase I/II sarcoma study, tumor control was suggested 
by longer PFS and OS in the higher dose cohorts compared to the 
low dose cohort. In the phase II osteosarcoma study, a   significant 
proportion of patients had SD by RECIST or PRs/SD by PET 
and CHOI criteria, suggesting increased sensitivity of PET and 
CHOI criteria for early detection of tumor responses to Rexin-G 
treatment. No DLT or organ-related toxicity was observed with 
prolonged  use  of  Rexin-G.  Correlative  analysis  showed  no 
  vector-neutralizing antibodies detected in serum, and no   evidence 
of vector DNA integration nor RCR in PBLs, further attesting 
to the overall safety of Rexin-G. Surgical resection of residual 
tumors following Rexin-G treatment—which enabled   histological 
examination,  as  well  as  strategic  tumor  debulking—followed 
by  the  administration  of  additional  postoperative  treatment, 
serves to underscore the potential clinical benefit of Rexin-G in 
  neoadjuvant/adjuvant protocols.
In  conclusion,  the  objectives  of  the  phase  I/II  Study  have 
been met. The overall safety of Rexin-G administered within the 
defined dose ranges was clearly established by the absence of DLT 
or   vector safety concerns. Further, the objectives of the phase 
II study for osteosarcoma have also been met, wherein tumor 
responses by RECIST of 10 SD of 17 evaluable patients (59%; 95% 
confidence interval, 33–82%) and a median PFS of ≥3 months and 
a median OS of 6.9 months in patients treated with at least 1 cycle, 
and 6 months in all enrolled patients, were demonstrated. Taken 
together, the results of these two independent well-defined phase 
I/II and phase II studies suggest that Rexin-G may help control 
tumor growth, and may possibly improve progression-free and 
OS times in chemotherapy-resistant sarcoma and osteosarcoma, 
thus hopefully providing the required elements for consideration 
of accelerated approval for osteosarcoma by the US Food and 
Drug Administration.19,20
MAterIAls And MetHods
Study  design.  The  phase  I/II  sarcoma  study  employed  a  modified 
cohort  of  three  design.21  Three  patients  were  treated  at  each  dose 
level with expansion to six patients per cohort if DLT was observed 
in one of the three first patients at each dose level. Each cohort was 
also expanded to six or seven patients if significant biologic activity 
was noted. Maximum tolerated dose was defined as the highest safely 
  tolerated dose, where ≤1 patient   experienced DLT, with the next higher 
dose level having at least two patients who experienced DLT. DLT was 
defined as any grade 3, 4, or 5 adverse event considered possibly, prob-
ably, or definitely related to the study drug, excluding grade 3 absolute 
neutrophil count lasting <72 hours, grade 3 alopecia, or any grade 3 or 
worse nausea, vomiting, or diarrhea where the patient did not receive 
maximal supportive care.22
Adaptive  Trial  Design:  A  phase  II  efficacy  component  was 
incorporated in the phase I/II sarcoma study by allowing additional 
treatment cycles to be given if the patient had ≤grade 1 toxicity. Further, 
across the board dose escalation was allowed by the Food and Drug 
Administration  when  the  safety  of  preceding  dose  levels  had  been 
documented.  The  principal  investigator,  S.P.C.,  was  also  allowed  to 
recommend surgical resection/debulking after at least one treatment 
cycle had been administered.
For the phase II osteosarcoma study, the optimal dose was derived 
from the results of the phase I/II sarcoma study. The number of patients 
enrolled was deduced from a statistical projection of 25% of patients 
achieving  SD  or  better  by  International  PET  criteria  and/or  RECIST, 
assuming that ≥95% of patients with chemo-resistant osteosarcoma will 
progress if untreated.3 Clinical toxicity was also reported according to 
severity and relatedness to the study drug.
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Figure 2  Analyses of overall survival of patients in the phase I/II sarcoma study and the phase II osteosarcoma study. Kaplan-Meier analyses 
show the survival curves of patients in (a) the phase I/II sarcoma study and (b) the phase II osteosarcoma study.
Figure  3  Histopathological  findings  in  the  lung  metastases  of  a 
patient  with  chemotherapy-resistant  osteosarcoma  after  rexin-G 
treatment. Representative H&E stained tissue sections from resected 
residual lung nodules in a Rexin-G treated patient. (a) 2.5 cm cystic mass 
with organized clot and rare osteosarcoma cells; (b) 0.9 cm calcified 
tumor mass with reparative fibrosis, immune infiltrate and osteosarcoma 
cells with rare mitosis.Molecular Therapy  vol. 17 no. 9 sep. 2009  1655
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Clinical  objectives/endpoints.  The  primary  objective  of  the  phase  I/II 
study for sarcoma is to determine the clinical toxicity of escalating doses 
of Rexin-G as defined by patient performance status, toxicity assessment 
score, hematologic, and metabolic profiles. The secondary objectives include 
(i) evaluation of the potential of Rexin-G for evoking an immune response, 
recombination  events  and/or  unwanted  vector  integration  in  nontarget 
organs, and (ii) identification of an antitumor response to Rexin-G.
The primary objective of the phase II study for osteosarcoma is to 
confirm the efficacy of Rexin-G in terms of tumor responses (complete 
response (CR), PR, or SD) by International PET criteria and by RECIST. 
A favorable tumor response was recorded if the patient had a CR, PR, or 
SD. The secondary objectives are (i) to confirm the efficacy of Rexin-G 
in terms of a median PFS of ≥1 month and a median OS of ≥6 months, 
and (ii) to evaluate the safety/toxicity of continued use of Rexin-G and 
the potential of Rexin-G for evoking an immune response, recombination 
events and/or unwanted vector integration in nontarget organs (PBLs).
Patient population. The phase I/II study included patients with a patho-
logic diagnosis of sarcoma who were refractory to standard chemotherapy, 
and the phase II study, patients with recurrent or metastatic osteosarcoma 
who were considered refractory to known therapies. Histologic or cytologic 
confirmation at diagnosis or recurrence was required. Inclusion criteria 
consisted of an Eastern Cooperative Oncology Group performance score 
of 0–1 and adequate hematologic, hepatic, and kidney function. Exclusion 
criteria included human immunodeficiency virus, hepatitis B virus, or 
hepatitis C virus positivity, clinically significant ascites, medical, or psychi-
atric conditions that could compromise successful adherence to the proto-
col, and unwillingness to employ effective contraception during treatment 
with Rexin-G and for 6 weeks following treatment completion. The clini-
cal protocols (C07-103 and C07-110) were reviewed and approved by the 
Western Institutional Review Board, Olympia WA 98502 and the Biosafety 
Committee of Epeius Clinical Research Unit, San Marino CA 91108.
Patient recruitment and assignment. The phase I/II and phase II stud-
ies  using  Rexin-G  for  sarcoma  and  osteosarcoma  were  registered  on 
www.  clinicaltrials.gov  (NCT00505713  and  NCT00572130,  respectively) 
within 1 week of study initiation, and patients were recruited on a first 
come first served basis after appropriate screening procedures were con-
ducted. Written informed consent, in accordance with the Declaration of 
Helsinski protocols, was obtained from each patient at the time of enroll-
ment. The phase I/II sarcoma study is an open label study using escalating 
doses of Rexin-G. Six patients were enrolled at dose level 0 followed by a 
dose escalation in seven patients at dose level I and another seven patients 
at dose level II when safety/toxicity data in at least three patients at lower 
dose levels had been recorded and no DLT was encountered. The phase II 
osteosarcoma study enrolled 22 patients at dose level II. Table 1 shows the 
demographics of all enrolled patients.
Treatment. Rexin-G is a nonreplicative “pathotropic” (pathology-  targeted) 
retroviral vector bearing a collagen-binding motif on its envelope   protein23 
and encoding an N-terminal deletion mutant construct of human cyclin 
G124  under  the  control  of  the  moloney  murine  leukemia  virus  long 
  terminal repeat promoter. The Rexin-G vector is produced by transient co-
transfection of three separate plasmids in 293T cells (human kidney 293 
cells transformed with the SV40 large T antigen) maintained as a fully vali-
dated master cell bank.17,25,26 The final product exhibits a viral titer of 5 × 
109 colony forming units (cfu) per milliliter, a biologic potency of 50–70% 
growth inhibitory activity in A375 melanoma cells, <550 bp residual DNA, 
no detectable E1A or SV40 large T antigen, and no detectable RCR.27 
The clinical vector is stored in volumes of 23 ml in 30 ml vials or 40 ml in 
150 ml cryobags in a −80 ± 10 °C freezer marked Biohazard. Preparation of 
the Rexin-G vector for patient administration consisted of rapid thawing 
of the vector in the vial or cryobag in a 34 °C waterbath. The vector was 
thawed 15–30 minutes prior to infusion into the patient, and was infused 
within 1 hour of thawing, intravenously over 5–10 minutes or at 4 ml/min. 
All personnel who handled and disposed of the vector observed Biosafety 
Level 2 compliance in accordance with the National Institutes of Health 
Guidelines for Research Involving Recombinant DNA molecules.
The  phase  I/II  sarcoma  study  enrolled  20  patients  who  received 
escalating doses of Rexin-G. Briefly, each treatment cycle was 6 weeks, 
consisting of 4 weeks treatment and 2 weeks rest period. The following 
two dose levels were employed: dose level 0 = 1 × 1011 cfu two times a week 
for 4 weeks (cumulative dose per cycle: 8 × 1011 cfu); dose level I = 1 × 
1011 cfu three times a week for 4 weeks (cumulative dose per cycle: 12 × 
1011 cfu); and dose level II = 2 × 1011 cfu three times a week (cumulative 
dose per cycle: 24 × 1011 cfu). The treatment cycles were repeated if the 
patient had grade 1 or less toxicity.
The phase II osteosarcoma study enrolled 22 patients who received 
dose level II or 2 × 1011 cfu three times a week for 4 weeks (cumulative 
dose per cycle: 24 × 1011 cfu), considered an optimal dose of Rexin-G for 
sarcoma. Some patients were started at 1 × 1011 cfu three times a week but 
the dose was eventually escalated to dose level II when safety at dose level 
I was documented in the phase I/II sarcoma study. The treatment cycles 
were repeated if the patient had grade 1 or less toxicity.
Safety and efficacy evaluation. Pretreatment evaluation included   history, 
physical exam, complete blood count with differential and platelet count, 
serum  chemistry  panel  including  aspartate  aminotransferase,  alanine 
  aminotransferase,  alkaline  phosphatase,  creatinine,  and  total  bilirubin, 
assessment  of  coagulation  including  prothrombin  time,  international 
  normalized ratio, and activated partial thromboplastin time, testing for 
human immunodeficiency virus, hepatitis B virus, and hepatitis C virus, 
imaging evaluation to include a whole body fludeoxyglucose/PET com-
puted  tomography  (CT)  scan,  electrocardiogram  and  chest  X-ray.  All 
patients had a   complete blood count and serum chemistry panel   performed 
weekly during treatment.
Safety analysis. Toxicity was assessed before and after each vector infu-
sion, and before beginning an additional treatment cycle. Patients had 
serum  collected  for  vector  antibody  detection  and  peripheral  blood 
mononuclear cells collected for assessment of vector DNA integration 
and RCR at the end of 4 weeks, at 6 weeks or before the start of a treat-
ment cycle.
Toxicity was graded using the National Cancer Institute Common 
Terminology Criteria Version 3.0.22 Overall evaluation of safety/toxicity 
was conducted by the principal investigator and associate (S.P.C. and 
V.S.C., respectively).
Correlative analysis. Correlative laboratory analysis was performed in the 
Epeius Biotechnologies Quality Control Unit, using standard operating 
procedures in compliance with good laboratory practices.28
Detection  of  antivector  antibodies  in  patients’  serum:  Testing  for 
the   presence of antivector antibodies was performed on serum samples 
obtained preinfusion and at 4 weeks and thereafter, at 6 weeks following 
treatment   initiation or before each treatment cycle.
Vector  neutralization  assay:  A375  cells  (ATCC,  Manassas,  VA), 
a human amelanotic melanoma cancer cell line, are incubated in 12-
well plates, at a   plating density of 0.8 × 104 cells per well, in Dulbecco’s 
modified  Eagle’s  medium  supplemented  with  10%  fetal  bovine  serum 
(D10). After overnight attachment, the cells are exposed to 1 ml of a 
mixture of Rexin-G vector and patient’s pre and post-treatment serum, 
fetal bovine serum and D10 (as controls) in the presence of Polybrene 
(8 µg/ml) for 2 hours at 37 °C, 5% CO2, with periodic rocking. Then, 1 ml 
fresh D10 is added, and the cultures are further incubated at 37 °C, 5% 
CO2. The medium is replaced with 1 ml fresh D10 the next day. To assess 
the dominant negative cyclin G gene product potency of the Rexin-G 
vector, the transduced cells are evaluated for their reduced proliferative 
potential by counting the number of viable cells in triplicate cultures at 1656  www.moleculartherapy.org  vol. 17 no. 9 sep. 2009     
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serial intervals (4 and 5 days) after transduction. This is our standard 
vector growth inhibition assay   calculated as follows:
To obtain the vector inhibitory activity in serum-treated and control 
cultures, the mean cell numbers in cultures transduced with mixtures of 
vector + D10 were compared with vector + serum-treated cultures and 
expressed as % vector inhibitory activity, using the following formula:
The presence of vector-neutralizing activity is detected by comparing 
the % inhibitory activity in mixtures of vector + D10 versus vector + 
serum using the following formula:
  % Vector-neutralizing activity =  
% inhibitory activity (vector + serum) −  
% inhibitory activity (patient baseline or fetal bovine serum)
A negative value indicates a drop in inhibitory activity. When the 
value is ≤10 no vector neutralization has occurred, and >10 neutralization 
has occurred.
Testing for antibodies against the gp70 envelope protein: Detection of 
serum antibodies against gp70 is conducted by western slot blot analysis 
using gp70 containing Rexin-G retroviral vector as a polyacrylamide gel 
electrophoresis resolved capture antigen incubated with either serum from 
treated patients or positive control gp70 murine monoclonal antibody.32 The 
appearance of an immunoreactive band on the Rexin-G slot blot at 70 kDa 
(gp70) in slot lanes of patient’s postinfusion serum indicates presence of 
patient postinfusion antibodies against the gp70 envelope protein.
Testing for the presence of RCR in patient PBLs: Testing for the presence 
of RCR was performed on DNA extracted from PBLs of treated patients, 
obtained at baseline (before vector infusion) and at the end of 4 weeks 
(after start of treatment). The assay was designed to detect the presence of 
RCR DNA sequences postvector infusion using PCR. In this study, real-
time PCR with an iCycler, Master mix reagents and optimized moloney 
murine  leukemia  virus  envelope  primers  is  used  to  amplify  a  small 
portion of the 2001 bp moloney murine leukemia virus envelope gene 
(164 bp fragment from 411 to 574 bp) present in our Rexin-G retroviral 
vector. Serial tenfold dilutions of control moloney murine leukemia virus 
envelope plasmid bovine epitope-retroviral envelope DNA in the picogram 
to femptogram range is diluted into control samples of human genomic 
DNA to establish a standard curve down to the limit of detection of the 
assay. Syber green DNA intercalation dye is used as a probe to monitor 
the progress of increased DNA quantities generated in the PCR reaction. 
MyIQ software records the real-time PCR reaction data and subsequently 
calculates the standard curve as well as the value for test patient samples. The 
real-time PCR results for amplification of the moloney murine leukemia 
virus envelope gene from 3 µg DNA (less if noted) patient lymphocyte 
genomic must be below the lowest result on the standard curve and or 
below preinfusion values to be considered “Negative” for RCR.
Vector DNA integration studies: Testing for presence of vector DNA 
  integration  was  performed  on  DNA  extracted  from  PBLs  obtained 
prein  fusion, 1 week, and at the end of 4 weeks or before the start of 
each   treatment cycle. Testing for vector DNA integration in PBLs was 
performed by centrifuging patient blood samples in a CPT collection 
tube to separate white blood cells from RBCs and serum. White blood 
cell  DNA  is  isolated  using  a  Qiagen  blood  DNA  isolation  kit,  then 
quantified with a UV spectro  photometer. Real-time PCR with an iCycler, 
Master mix reagents and optimized Neo primers are used to amplify a 
small portion of the 795 bp Neomycin Phosphotransferase gene (75 bp 
fragment  from  382  to  456 bp)  present  in  our  dnG1-Erex  retroviral 
vector.  Serial  tenfold  dilutions  of  Rexin-G  retroviral  vector  control 
plasmid dnG1-Erex DNA in the pico to femptogram range is diluted 
into control human genomic DNA to establish a standard curve down 
to the limit of detection of the assay. Syber green DNA intercalation 
dye  is  used  as  a  probe  to  monitor  the  progress  of  increased  DNA 
quantities generated in the PCR reaction. MyIQ software records the 
real-time PCR reaction data and subsequently calculates the standard 
curve as well as the value for test patient samples. The real-time PCR 
results for amplification of the neomycin phosphotransferase gene from 
patient lymphocyte genomic DNA must fall below the lowest result on 
the standard curve and or below preinfusion values to be considered 
“Negative” for vector integration.
Efficacy  analysis.  Efficacy  assessment  with  fludeoxyglucose  PET/CT 
scan was also performed at the end of 4 weeks, and at the end of 6 weeks 
or before starting an additional treatment cycle up to 12 weeks, and every 
12 weeks thereafter. All PET/CT images were performed and reviewed 
by independent radiologists of the Medical Imaging Center of Southern 
California, Santa Monica, who are experts at nuclear and PET imag-
ing and who were blinded to the Rexin-G dose levels. Tumor response 
was evaluated using the standard National Cancer Institute RECIST 
criteria,29  the  International  PET  criteria,30  and  the  CHOI  criteria,31 
according to Food and Drug Administration-approved   protocols for 
tumor response assessment.
The modified International PET Criteria defines a CR as disappear-
ance  of  fludeoxyglucose  avid  uptake  in  target  and  nontarget  lesions 
with no new lesions; PR as a decrease in maximum standardized uptake 
value  of  >25%  from  baseline  with  no  new  lesions  and  no  obvious 
progression  of  nontarget  lesions;  SD  as  not  meeting  the  criteria  for 
CR, PR or PD and no symptomatic deterioration attributed to tumor 
progression; and PD as an increase in maximum standardized uptake 
value of >25% from baseline, any new lesions, and obvious progression 
of nontarget lesions.30
The modified CHOI Criteria defines CR as the disappearance of all 
disease and no new lesions; PR as a decrease in size of ≥10% or a decrease 
in CT density (HU) ≥15% with no new lesions and no obvious progression 
of nonmeasurable disease; SD as not meeting the criteria for CR, PR or 
PD and no symptomatic deterioration attributed to tumor progression; 
and PD as an increase in unidimensional tumor size of >10% and did not 
meet criteria for PR by CT density, any new lesions, including new tumor 
nodules in a previously cystic tumor.31
Overall evaluations of tumor responses, PFS and OS were conducted by 
the principal investigator and associate (S P C and V S C, respectively).
Statistical  analysis. Frequency tables, graphs, and summary statistics 
were used to describe patient characteristics and outcome data for both 
phase I/II and phase II studies. Clinical data from 1 August, 2007 to 29 
October, 2008 were analyzed. Kaplan-Meier methodology16 was used to 
describe graphically the distribution of OS. OS time was calculated in 
days and divided by 30.4 to convert to months. PFS time was approxi-
mated, using the times of patient evaluations. OS and PFS times were 
compared in groups of patients treated at different dose levels, using 
permutation tests on the logrank statistic with at least 10,000 replica-
tions. Tumor response data by different specific criteria (RECIST, PET 
or CHOI criteria) were reported. Reported P-values are two-sided, and 
P < 0.05 was considered statistically significant. Analysis was done using 
NCSS software (Number Cruncher Statistical Systems, Kaysville, Utah). 
Statistical  analysis  was  performed  by  a  biostatistician  not  otherwise 
involved in the study (W.C.B.).
% Vector inhibitory activity (vector +D10) = 
No. of cells ( (D10) No. of cells (vector + D10)
No. of cells (D10)
−
×100
Serum   vector inhibitory activity (vector + serum) = 
No. 
%
o of cells (D10) No. of cells (vector + serum)
No. of cells 
−
( (D10)
×100Molecular Therapy  vol. 17 no. 9 sep. 2009  1657
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